iCAD Announces Schedule of Events and Featured Quantitative Image Analysis Solutions at the 2010 RSNA

NASHUA, N.H., Nov. 22, 2010 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces its schedule of events at the 96th annual meeting of the Radiological Society of North America (RSNA) in Chicago, from November 28 through December 3, 2010.

"At the RSNA this year, iCAD will continue to work with thought leaders in the radiology field and healthcare advocates to change the diagnostic paradigm for breast, prostate and colon cancers so that more people can access advanced imaging solutions for earlier detection of these prevalent cancers," said Ken Ferry, President and CEO of iCAD. "Our recently FDA cleared CT Colonography technology, VeraLook™, is expected to generate great interest this year, as continued research and data analysis show the promise of virtual colonography for improving patient adherence to guidelines supporting screening for colorectal cancer. Our leading-edge technologies for CAD applied to digital mammography and breast MRI are also expected to draw continued attention to this audience of more than 60,000 medical, scientific and corporate professionals."  

Important educational exhibits and scientific papers discussing the use of computer-aided detection (CAD) and other advanced image analysis solutions for the early detection of cancer include:

• On Monday, November 29, iCAD will participate in the International Prostate MRI Working Group, in conjunction with AdMeTech Foundation. Modeled on the Breast Cancer MRI Working Group, the goal of this group is to foster dialogue between academia, leading physicians, prostate cancer advocacy groups and industry to review emerging scientific data in order to expedite the advancement of MRI technologies and their use in the diagnosis and management of prostate cancer.  
• iCAD will participate in the Quantitative Imaging Reading Room, an educational exhibit showcase highlighting products and applications that integrate quantitative analysis and structured reporting into the image interpretation and reporting process. iCAD's poster, "Quantitative Image Suite Applied in Research and Clinical Practice," will be on display Sunday through Thursday.
• An educational exhibit  titled, "Optimizing Computer-aided Detection for CT Colonography: Understanding Stand Alone Software Accuracy," Code: LL-GIE2306, by Dr. Abraham Dachman, Professor of Radiology and Director of Fellowship Programs at the University of Chicago will be on display in the Lakeside Learning Center.
• An educational exhibit titled, "Optimizing Time-efficient Use of Computer-aided Detection in Computed Tomographic Colonography (Virtual Colonoscopy)," Code: LL-GIE2302, by Dr. Abraham Dachman, will be on display in the Lakeside Learning Center.
• A scientific (formal) paper presentation titled, "CT Colonography of Nonpolypoid Colorectal Lesions: CAD-assisted versus Unassisted Reading by Radiologists with Different Levels of Experience," Code: SSQ05-07, will be presented by Dr. Franco Iafrate of the Sapienza University of Rome on Thursday, December 2nd at 10:30 am in room E353C.

In addition, iCAD will host several mini educational sessions at its booth, #6216 in South Building, Hall A, located at McCormick Place.  Sessions will be held daily at 10:30, 12:30, 2:30 and 4:30 and will cover such topics as DCE Protocol Optimization for Breast MRI, Treatment Planning with CyberKnife® Robotic Radiosurgery System and iCAD's VividLook quantitative image analysis solution. For a complete list of sessions, please visit iCAD's page on the RSNA online press room or the iCAD website at http://www.icadmed.com/newsevents/rsna2010.htm.

Product Information

iCAD will be showcasing the following solutions in their RSNA booth:

• VividLook DCE MRI, iCAD's prostate image analysis solution
• SpectraLook DCE MRI, iCAD's breast image analysis solution
• OmniLook, a complementary software module to iCAD's existing breast MRI (SpectraLook) and prostate MRI (VividLook) solutions, applies advanced image analysis using a pharmacokinetic model for tumor assessment in other organs, such as the liver, kidney and brain
• PrecisionPoint, iCAD's interventional planning solution for breast MRI, and VersaVue Enterprise, iCAD's MRI review software solution
• VeraLook™, the first FDA cleared CAD solution for virtual colonoscopy (CTC)
• The new SecondLook® Premier*, iCAD's latest SecondLook Digital CAD solution for digital mammography
• SecondLook® Digital Multi Vendor Solution (MVS), which allows hospitals and imaging facilities to process cases from many digital mammography systems using a single server

To schedule a demonstration of iCAD's advanced image analysis solutions, please visit http://www.icadmed.com/newsevents/rsna2010.htm and click the "Schedule a Demo" button.

*Available outside US only.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company's first breast cancer detection product in 2002, more than 4,000 iCAD systems have been placed in healthcare practices worldwide. iCAD's solutions aid in the early detection of the most prevalent cancers including breast, prostate, colon, and in the future, lung cancer.  For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

SOURCE iCAD